This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): trans-ISA247, ISA247, LX211, voclosporin, Voclera (Canada)
Description: BioMedTracker has separate drug profiles for voclosporin. Please also see LX214 for the topical formulation.
Luveniq (voclosporin) is an immunosuppressive drug in the class of calcineurin inhibitors. Luveniq reversibly inhibits immunocompetent lymphocytes, particularly T-lymphocytes, and also inhibits lymphokine production and release.
Roche and Isotechnika
On April 9, 2002, Isotechnika entered into a Development Collaboration and LicensingAgreement with Roche for the global co-development and commercialization of voclosporin. Under terms of the agreement,Isotechnika could receive up to an aggregate of $215 Million USD comprised of upfrontlicense fees, development and commercial milestones, and equity investment. TheCompany will also receive tiered, progressive sales-based royalties at varying rates uponcommercialization of voclosporin. Roche also is responsible for seventy percent of the shareddevelopment costs of voclosporin as defined by the collaboration agreement with Isotechnikaresponsible for the remaining thirty percent.
On April 19, 2004, Isotechnika and Roche amended the collaboration agreement for the development and commercialization of voclosporin in transplantation. Under the amended terms of the collaboration agreement, Isotechnika has control over clinical development, manufacturing...See full deal structure in Biomedtracker
Partners: Atrium Medical Corporation Lux Biosciences Aurinia Pharmaceuticals Inc. 3SBio Inc. The Galenica Group
Additional information available to subscribers only: